6 October 2015 - - US-based biotechnology company Rodin Therapeutics has appointed Adam J. Rosenberg as chief executive officer, the company said on Tuesday. Rosenberg will also be appointed to Rodin's board of directors. Since its inception within Atlas Venture's company-creating seed program in March 2013, Rodin has advanced its internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series discovered at the Broad Institute. Collaborations with co-founding structure-accelerated lead discovery partner Proteros Biostructures, as well as with the Alzheimer's Drug Discovery Foundation, have been put in place as well, Rodin said. Rosenberg most recently served as co-founder, director and chief executive officer at Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology and novel high throughput screening technologies to discover new treatments for central nervous system disorders. He will retain this position until a successor is hired. Rosenberg also co-founded and served on the board of directors of Clean Membranes, a materials company based on MIT technology, and since 2009 has advised or served in interim executive roles with numerous companies in the healthcare and biotechnology sectors, including leading the digital health strategy for Brightstar (acquired by SoftBank) and serving on the advisory board of Gecko Health Innovations (acquired by Teva Pharmaceuticals). From 2005 to 2009, he co-founded and served as CEO of Link Medicine Corp., a company focused on developing novel disease-modifying neurodegenerative treatments. Link's lead program was acquired by AstraZeneca. He also co-founded Faber Law Group, a boutique business law firm focused on the biotechnology sector. Previously, Rosenberg was a principal with Ovation Capital Partners, and worked in the corporate finance and venture capital groups at leading law firms in Boston, Seattle and New York. Rodin Therapeutics is discovering and developing first in class therapeutics for cognitive disorders, applying unique insights into the role of epigenetics and best in class structural biology capabilities. The company closed a USD 12.9m series A financing round in May 2014, and was co-founded in 2013 by Atlas Venture and Proteros Biostructures. Atlas Venture is a biotech-focused, early-stage venture capital firm that creates and invests in life sciences startup companies in the US Atlas is based in Cambridge, Massachusetts. Since 1993, Atlas has invested in over 150 early stage life sciences companies.